Bimini Biotech BV

BIMINI Biotech was founded based on 30 years of work on the GH/IGF-1 axis at the lab of Prof. Ger Strous. Our lead compounds have shown extremely promising in vitro and in vivo efficacy for various cancer types (lung, skin, bone, colon). We are currently pursuing our lead assets for the treatment of colorectal cancer, a deadly disease with a huge socio-economic impact. Our approach is based on a novel method of targeting the GH/IGF-1 axis via a unique mode of action, thus delivering solid efficacy results.

We aim to become a leading innovator in GHR based therapeutics in oncology, metabolic disorders and ageing. To do so, we identify and develop  novel compounds that target GHR-related pathways and bring them to the clinic. After successful demonstration of safety and (initial) efficacy (Phase 2b), we will out-license the IP on the compound to a biopharmaceutical partner in a lucrative milestone/royalty deal. 

Our team combines young ambition with seasoned biotech entrepreneurs, innovation and funding experts, and renowned scientific leaders. The team has shown track-record in all phases of biotech development, from academic research to successful exit deals. The management of the company is performed by Maurits van den Nieuwboer PhD and Digvijay Gahtory PhD. The Scientific director is Prof. Ger Strous (Emeritus Hoogleraar Celbiologie UMC Utrecht), a key-opinion-leader in the field of the GH/IGF-1 axis.